rROP2 from Toxoplasma gondii as a potential vaccine against oocyst shedding in domestic cats

• Autor(a) principal: Zulpo,Dauton Luiz
• Data de Publicação: 2017
• Outros Autores: Igarashi,Michelle, Sammi,Ana Sue, Santos,Joeleni Rosa dos, Sasse,João Pedro, Cunha,Ivo Alexandre Leme da, Taroda,Alessandra, Barros,Luiz Daniel de, Almeida,Jonatas Campos de, Jenkins,Mark Christopher, Navarro,Italmar Teodorico, Garcia,João Luis
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Revista Brasileira de Parasitologia Veterinária (Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1984-29612017000100067
• topic: Definitive host; immunization; recombinant protein; toxoplasmosis

Abstract The aim of the present study was to evaluate oocyst shedding in cats immunized by nasal route with T. gondii proteins ROP2. Twelve short hair cats (Felis catus) were divided in three groups G1, G2 and G3 (n=4). Animals from G1 received 100 μg of rROP2 proteins plus 20 μg of Quil-A, G2 received 100 μg of BSA plus 20 μg of Quil-A, and the G3 only saline solution (control group). All treatments were done by intranasal route at days 0, 21, 42, and 63. The challenge was performed in all groups on day 70 with ≅ 800 tissue cysts of ME-49 strain by oral route. Animals from G1 shed less oocysts (86.7%) than control groups. ELISA was used to detect anti-rROP2 IgG and IgA, however, there were no correlation between number of oocyst shedding by either IgG or IgA antibody levels. In the present work, in spite of lesser oocysts production in immunized group than control groups, it was not possible to associate the use of rROP2 via nostrils with protection against oocyst shedding. For the future, the use of either other recombinant proteins or DNA vaccine, in combination with rROP2 could be tested to try improving the efficacy of this kind of vaccine.